Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Finished Goods (2017 - 2025)

Adma Biologics (ADMA) has disclosed Finished Goods for 9 consecutive years, with $52.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Finished Goods rose 8.18% year-over-year to $52.1 million, compared with a TTM value of $52.1 million through Dec 2025, up 8.18%, and an annual FY2025 reading of $52.1 million, up 8.18% over the prior year.
  • Finished Goods was $52.1 million for Q4 2025 at Adma Biologics, down from $64.3 million in the prior quarter.
  • Across five years, Finished Goods topped out at $70.3 million in Q4 2023 and bottomed at $17.5 million in Q2 2021.
  • Average Finished Goods over 5 years is $51.5 million, with a median of $52.3 million recorded in 2023.
  • The sharpest move saw Finished Goods skyrocketed 257.16% in 2022, then tumbled 32.47% in 2025.
  • Year by year, Finished Goods stood at $29.0 million in 2021, then surged by 101.6% to $58.5 million in 2022, then increased by 20.22% to $70.3 million in 2023, then plummeted by 31.54% to $48.1 million in 2024, then rose by 8.18% to $52.1 million in 2025.
  • Business Quant data shows Finished Goods for ADMA at $52.1 million in Q4 2025, $64.3 million in Q3 2025, and $47.9 million in Q2 2025.